You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Merck
McKinsey
Dow
Johnson and Johnson

Last Updated: October 28, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,968,595

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,968,595 protect, and when does it expire?

Patent 9,968,595 protects TIBSOVO and is included in one NDA.

This patent has seventeen patent family members in thirteen countries.

Summary for Patent: 9,968,595
Title:Pharmaceutical compositions of therapeutically active compounds
Abstract: Provided are compounds and pharmaceutical compositions useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound or pharmaceutical composition described herein.
Inventor(s): Gu; Chong-Hui (Waban, MA)
Assignee: AGIOS PHARMACEUTICALS, INC. (Cambridge, MA)
Application Number:15/125,880
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Process;

Drugs Protected by US Patent 9,968,595

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial Y A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)   Start Trial
Agios Pharms Inc TIBSOVO ivosidenib TABLET;ORAL 211192-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial Y TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,968,595

PCT Information
PCT FiledMarch 13, 2015PCT Application Number:PCT/US2015/020349
PCT Publication Date:September 17, 2015PCT Publication Number: WO2015/138839

International Family Members for US Patent 9,968,595

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015229214   Start Trial
Australia 2019246824   Start Trial
Brazil 112016021232   Start Trial
Canada 2942072   Start Trial
China 106255498   Start Trial
Eurasian Patent Organization 201691845   Start Trial
European Patent Office 3116492   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
Boehringer Ingelheim
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.